Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding, in patients with advanced solid tumors.

AU-007 - Aulos Biosci

Proleukin (aldesleukin) - Clinigen, Novartis, Prometheus

James Robert Vasselli; Sophia Frentzas; Andrew James Weickhardt; Paul L. de Souza; Jenny Tang; Tim Wyant; Inbar Amit; Yanay Ofran; Aron Knickerbocker

Apr 28, 2022